DAIICHI-SANKYO
26.4.2021 09:02:10 CEST | Business Wire | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA® (edoxaban) in protecting against the risk of stroke in people with atrial fibrillation (AF). Over 13,000 patients were followed for two years in the ETNA-AF-Europe study, showing stroke and bleeding rates in line with rates seen after one year of follow-up. The data were presented at the annual scientific meeting of the European Heart Rhythm Association (EHRA 2021).1
“AF is a long-term condition which puts people at an increased risk of stroke, so it is very important that we have treatments that can provide benefits over the long term,” said Joris R. de Groot, MD, PhD, FESC, Professor of Cardiac Electrophysiology and Atrial Fibrillation at University of Amsterdam; Cardiologist at the Amsterdam University Medical Centers, Amsterdam the Netherlands. “We are seeing that more frail patients receiving the lower dose of edoxaban are not at increased risk of intracranial haemorrhage and are benefitting from treatment. This underlines the importance of prescribing anticoagulant therapy even for ageing AF patients.”
Event rates for stroke and death were 0.69% and 3.80% per year respectively. Some patients were prescribed the lower dose of edoxaban (30mg) for reasons including renal impairment. Annual event rates of intracranial haemorrhage were similar for both 60mg (0.2%) and 30mg (0.22%) doses. As a study investigating treatment in routine clinical practice, the data show that the majority of patients were using the recommended dose (83%).
The two-year outcome data in 13,417 patients across 10 European countries were from the European ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) programme, a non-interventional safety study evaluating edoxaban treatment in routine clinical practice for AF. ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study programme investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date.
Additional data in 27,617 people with AF from the global ETNA-AF programme were also presented at EHRA 2021, confirming that the stroke and bleeding rates under use of edoxaban at two years were also considered low and in line with randomised clinical trials in this larger, global data set. Patients with AF benefitted from edoxaban treatment across age groups, including the very elderly (≥85 years), in routine clinical care.2,3
“These data underline the importance of providing effective treatment for elderly and frail AF patients, who are already at higher risk of strokes and, as confirmed by these real-world data, benefit from edoxaban treatment,” said Dr. Garth Virgin, Executive Director Medical Affairs Specialty Medicines at Daiichi Sankyo Europe. “The ETNA-AF programme is a huge undertaking that is providing critical insights into patient outcomes in routine clinical practice, and we are truly grateful for all the healthcare professionals and patients who are helping to make it possible.”
-ENDS-
About ETNA-AF: https://www.daiichi-sankyo.eu/media/about-etna-af
About AF: https://www.daiichi-sankyo.eu/media/about-etna-af
About Edoxaban: https://www.daiichi-sankyo.eu/media/about-etna-af
About the Edoxaban Clinical Research Programme, EDOSURE: https://www.daiichi-sankyo.eu/media/about-etna-af
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com .
Forward-looking statements: https://www.daiichi-sankyo.eu/media/about-etna-af
References
1 De Caterina R, et al. Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study. Presentation at EHRA Congress 2021.
2 Dinshaw L, et al . Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: Results from the global noninterventional ETNA-AF program. Presentation at EHRA Congress 2021.
3 Morrone D, et al . Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across all age groups: Two-year results from ETNA-AF. Presentation at EHRA Congress 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 15:00:00 CEST | Press release
Veteran investment management executive will lead global sales, client engagement and marketing as Boyd Watterson Global continues expanding its global alternatives platform across real estate, infrastructure, and debt strategies. Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilitie
Trulioo Launches AI Agent to Resolve Beneficial Ownership Where Global Registries Fall Short23.7.2026 15:00:00 CEST | Press release
Breakthrough AI agent reconstructs ownership for long-tail businesses and hard-to-reach jurisdictions while significantly increasing UBO coverage Trulioo, a global risk intelligence platform, today announced the UBO Discovery Agent, the newest layer in Trulioo's UBO Discovery capability inside its business risk and Know Your Business (KYB) verification workflow. AI is reshaping fraud, making it easier for bad actors to hide, and harder for companies to catch them. This makes the already tough job of verifying who actually owns a business even more difficult. Determining a business's ultimate beneficial owner is an ongoing, acute challenge for companies: registry coverage is inconsistent across countries, and even where registries exist, they typically record shareholders and directors of record (rather than the people actually in control). That data isn't simply outdated, it reflects a structural lag: ownership changes and time passes before the filing is made and processed, so a looku
Humanoid Raises $152 Million at $1.35 Billion Post-Money Valuation, Becoming Europe's First Pure-Play Humanoid Robotics Unicorn23.7.2026 15:00:00 CEST | Press release
Humanoid announces its Series A investment round, reaching a $1.35 billion valuation just two years after founding.It is the largest ever Series A for a humanoid-first robotics company in Europe, positioning Humanoid as the leading humanoid-first robotics unicorn in the UK and continental Europe.The new capital will accelerate Humanoid's next-generation robot development, commercial deployments with global industrial leaders, and evolution of the proprietary AI platform on the path toward general-purpose humanoids.The investment marks a defining moment for Europe's tech ecosystem, showing that globally competitive Physical AI companies can be built and scaled in Europe. Humanoid, a UK-based AI and robotics company building industrial humanoid robots, announced a $152 million Series A financing at a $1.35 billion post-money valuation. This funding brings the total amount raised to date to $270 million. The round was led by Prime Movers Lab, a venture capital firm focused on investments
Riskified Named to the CNBC World's Top Fintech Companies 2026 List23.7.2026 14:00:00 CEST | Press release
Payment category recognition marks Riskified's continued presence among the world's leading fintech innovators Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, has been named to CNBC's World's Top Fintech Companies 2026 list, in the Payments category. The list, now in its fourth edition, is produced by CNBC in partnership with Statista Inc., the global statistics and industry ranking firm. It was announced on July 22, 2026, and is available on CNBC's website. This is Riskified's second time making the list. The company previously earned this recognition in 2024, reinforcing its position in the ecommerce fraud and risk intelligence sector and underscoring its ongoing success in empowering businesses to grow revenue and profitability by mitigating risk through its AI-powered platform. CNBC and Statista's ranking covers the top 500 companies across eight fintech segments — Payments, Neobanking, Alternative Financing, Wealth Technology, Digital As
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom